A Borghetti
Overview
Explore the profile of A Borghetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
204
Citations
469
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iannone V, Lombardi F, Ciccullo A, Lamanna F, Salvo P, Sanfilippo A, et al.
AIDS Behav
. 2025 Jan;
PMID: 39779624
The new Cabotegravir + Rilpivirine long acting (CAB + RPV) is the injectable regimen for treatment-experienced people with HIV (PWH). Little data from real-world settings are available, particularly in more...
2.
Passerotto R, Lamanna F, Salvo P, Iannone V, Steiner R, Carbone A, et al.
Antivir Ther
. 2024 Dec;
29(6):13596535241306467.
PMID: 39698926
Introduction: BIC/FTC/TAF showed efficacy and tolerability in randomized trials as a switch strategy in virologically-suppressed people living with HIV. We evaluated its effectiveness in a real-life setting. Methods: A retrospective...
3.
Borghetti A, Alkhatib M, Dusina A, Duca L, Borghi V, Zazzi M, et al.
J Antimicrob Chemother
. 2021 Dec;
77(3):740-746.
PMID: 34849981
Objectives: To compare the efficacy of dolutegravir plus lamivudine dual therapy (DT) with that of dolutegravir plus two NRTIs triple therapy (TT) as switch strategies. Methods: A multicentre cohort of...
4.
Borghetti A, Ciccullo A, Lombardi F, Baldin G, Belmonti S, Prosperi M, et al.
HIV Med
. 2020 Sep;
22(1):22-27.
PMID: 32964671
Objectives: Nucleoside reverse transcriptase inhibitor (NRTI) transmitted drug resistance mutations (TDRMs) could increase the risk of virological failure (VF) of first-line integrase strand transfer inhibitor (InSTI)-based regimens. Methods: Patients starting...
5.
Ciccullo A, Borghetti A, Dusina A, Segala F, Visconti E, Tamburrini E, et al.
HIV Med
. 2020 Sep;
22(1):e3-e4.
PMID: 32876390
No abstract available.
6.
Borghetti A, Ciccullo A, Paratore M, Rovedi F, Stella L, Marchetti A, et al.
J Infect
. 2020 May;
82(1):159-198.
PMID: 32473233
No abstract available.
7.
Borghetti A, Moschese D, Cingolani A, Baldin G, Speziale D, Ciccullo A, et al.
HIV Med
. 2019 Jun;
20(9):624-627.
PMID: 31240860
Objectives: Two-drug antiretroviral regimens based on lamivudine (3TC) plus either a protease inhibitor (PI) or dolutegravir (DTG) are becoming increasingly popular in switch strategies. Our goal was to derive a...
8.
Bellino S, Borghetti A, Lombardi F, Camoni L, Ciccullo A, Baldin G, et al.
Epidemiol Infect
. 2019 Mar;
147:e89.
PMID: 30869037
Here we evaluated hospitalisation rates and associated risk factors of human immunodeficiency virus (HIV)-infected individuals who were followed up in an Italian reference hospital from 1998 to 2016. Incidence rates...
9.
Borghetti A, Calcagno A, Lombardi F, Cusato J, Belmonti S, DAvolio A, et al.
J Antimicrob Chemother
. 2018 Dec;
74(4):1035-1043.
PMID: 30561642
Background: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2),...
10.
Borghetti A, Baldin G, Lombardi F, Ciccullo A, Capetti A, Rusconi S, et al.
HIV Med
. 2018 Mar;
PMID: 29573320
Objectives: We evaluated the efficacy and tolerability of lamivudine + dolutegravir in a cohort of HIV-1 infected, treatment-experienced patients with undetectable HIV-RNA. Methods: Time to treatment discontinuation (TD) and virological...